FIELD: pharmaceutical industry.
SUBSTANCE: what is presented is using a combination containing a biocompatible polymer and a eukaryotic cell selected from autologous mesenchymal bone marrow or adipose tissue stem cells, for prevention and/or treatment of tissue damages selected from skin lesions, bone tissue damages, muscular tissue injuries, locomotor disorders, digestive system lesions, pulmonary tissue injuries. Said biocompatible polymer has general formula (I) AaXxYy or general formula (II) AaXxYyZz, where A is a glucose-containing monomer; X is group R1COOR2; Y is group -R7SO3R8; Z is an acetate group; R1 is C1-C6 aliphatic hydrocarbon chain which can be branched and/or unsaturated; R2 and R8 are a hydrogen atom or an alkali metal cation; R7—bond; a is the amount of monomers such that the weight of said biocompatible polymers is greater than 2000 Da; x is the degree of substitution of monomers A in X groups and is equal to 20–150 %; y is degree of substitution of monomers A in Y groups and is equal to 30–150 %; z is degree of substitution of monomers A in Z groups and is equal to 0–50 %.
EFFECT: invention provides higher clinical effectiveness in tissue injuries and accelerated healing.
3 cl, 7 ex, 1 tbl
Authors
Dates
2020-05-15—Published
2016-05-26—Filed